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Abstract 
Introduction: As both anti-tumour effects and toxicity are thought to be dose-dependent, 
patients with the greatest toxicity may also have the best outcome. We assessed whether 
severity of doxorubicin-induced hematological toxicity is associated with outcome in advanced 
soft tissue sarcoma (STS) patients. Additionally, risk factors for hematological toxicity were 
explored.  
Methods: Worst haematological toxicities (anaemia, leukopenia, neutropenia and 
thrombocytopenia) seen during treatment were scored according to CTCAE toxicity score. 
Differences in overall survival (OS), progression free survival (PFS) and response rate (RR) 
between patients with or without high haematological toxicity (grades 0-2 vs 3-4) were 
assessed using conventional statistical tests. Associations between baseline characteristics and 
hematological toxicity were established using logistic multivariate regression. 
Results: In 557 patients eligible for this analysis, 47.2% of the patients received at least 6 cycles 
of treatment; 45% stopped treatment early due to progression, 3% because of toxicity. Relative 
dose intensity (RDI) was constant over the cycles.  
OS, PFS, and RR did not differ between patients with grade 3/4 toxicity during treatment versus 
those with grade 1/2. Risk factors for grade 3/4 haematological toxicity, in particular 
neutropenia, were age above 60 years, low BMI, and female gender.   
Conclusion: In this large series, risk factors for haematological toxicity in STS patients receiving 
doxorubicin monotherapy were revealed. The finding that there was no association between 
outcome and haematological toxicity during doxorubicin treatment may be useful to reassure 
advanced STS patients that failure to experience haematological toxicity during treatment does 
not equate to under-treatment.   
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Introduction. 
Soft tissue sarcomas (STS) are a rare group of tumours consisting of numerous different 
subtypes displaying great variation in molecular characteristics, clinical behaviour, and 
sensitivity to anti-tumour agents. Patients with advanced disease not amenable to local 
treatment options with curative intent have a dismal prognosis, with a median overall survival 
of approximately 1 year. For these patients, palliative treatment is indicated.  
In the first line setting, numerous drugs have been shown to exert anti-tumour activity. Of 
these, doxorubin and ifosfamide are the most commonly used agents. Given equivalent efficacy 
of doxorubicin and ifosfamide (1), doxorubicin is preferred given more convenience for the 
patients as doxorubicin can be administered once every 3-weeks in an out-patient setting. 
Recently, a randomised EORTC study compared doxorubicin monotherapy versus the 
combination of doxorubicin and ifosfamide (2). Although response rate and progression-free 
survival were greater in the patients treated with the combination, overall survival, the primary 
endpoint in this study, was not statistically different. Consequently, apart from patients whose 
primary need is tumour shrinkage, have a good clinical condition and adequate organ function 
and for whom the combination may be preferred, doxorubicin monotherapy is still considered 
standard for the majority of advanced STS patients (3). Recently it was shown in a randomized 
phase II study that the addition of the anti-platelet-derived growth factor receptor-alpha 
(PDGFRA) monoclonal antibody, olaratumab, to doxorubicin improved overall survival 
compared with doxorubicin alone (4) resulting in approval of this drug in combination with 
doxorubicin. But given the preliminary nature of these results, in many centres doxorubicin will 
remain the mainstay of treatment for many advanced STS patients.   
The most commonly used schedule of doxorubicin monotherapy in advanced STS patients is 75 
mg/m2 every three weeks for a maximum of 6 cycles. As holds true for all anti-tumour agents, 
the pharmacokinetics of doxorubicin and its metabolites greatly differs between patients. This 
large variety in doxorubicin PK between patients may partially account for the great variation in 
toxicities experienced by patients (5). Accordingly, a statistically significant association was 
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revealed between systemic doxorubicin blood levels and myelosuppression in a small series of 
patients with small cell lung cancer (6). 
Given this relationship between systemic exposure to doxorubicin and haematological toxicity 
on one hand and a suggested dose-response association for doxorubicin in advanced STS (7) on 
the other hand, a relationship between doxorubicin-induced toxicity and outcome may exist in 
advanced STS. It is important to know whether such a relationship indeed exists in advanced 
STS for a number of reasons. In daily practice, many patients who do not experience any 
significant toxicity from doxorubicin are worried about whether or not the treatment “works”, 
in other words whether the chemotherapy actually exerts anti-tumour effects. Furthermore, if 
such a relationship does exist, the occurrence and severity of toxicity might be an early marker 
for response and in principle, could serve to guide treatment, i.e. increasing the dose up to 
toxicity. 
In this study, we retrospectively examined the relationship between the severity of 
haematological toxicities and efficacy in a large series of advanced STS patients treated with 
first-line doxorubicin monotherapy. Additionally, risk factors for haematological grade 3/4 
toxicity were explored.  
   
Patients and methods. 
Patients. 
In the EORTC database, 9 studies were identified in which advanced STS patients were treated 
with doxorubicin monotherapy 75 mg/m2 every 3 weeks. No G-CSF, erythropoietin or 
dexrazoxane was allowed in any of the studies. In case of toxicity, dose reduction had to be 
applied. This analysis was focused only on patients who received at least one cycle of treatment 
and with at least one post-baseline laboratory assessment leaving a total of 7 eligible EORTC 
trials conducted between 1990 and 2012 with in total 557 patients eligible for this analysis 
(supplementary table 1).  
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Endpoints. 
The endpoints for outcome considered for this analysis were overall survival (OS), progression-
free survival (PFS) and response rate (RR). OS was defined as the time elapsing between the 
date of randomization (in the randomized trials) or registration (in the nonrandomized trials) 
and the date of death. Patients alive at the last follow up date were censored. PFS was defined 
as the time between date of randomization (in the randomized trials) or registration (in the 
nonrandomized trials) and the date of first progression or death, whichever came first. Patients 
who are alive without progression at the last follow up date are censored. RR was evaluated in 
all trials using WHO response criteria or RECIST in which patients who achieved a complete or 
partial response were considered as “responders”, and patients with stable disease or in 
progression are considered as “non-responders”. Best responses were used. 
 
Risk factors. 
This analysis was focused on four hematological toxicities: anaemia, leukopenia, neutropenia, 
and thrombocytopenia. For each of the four toxicities, the Common Terminology Criteria for 
Adverse Events version 4.0 (CTCAE v4.0) scoring from grade 0 to grade 4 was used. Patients 
experiencing grade 0-2 toxicity as the highest toxicity during treatment were considered as 
patients with “low toxicity”, those patients with grade 3-4 toxicity as most severe toxicity 
during treatment as patients with “high toxicity”.  
In all but two studies ,a full blood count was done weekly. In the two other studies (EORTC 
62901 (N = 112) and EORTC 62091 (N = 43), a full blood count was mandated during the first 
two cycles and then prior to each subsequent administration of doxorubicin. However, 
additional analyses (results not shown) showed that many investigators obtained weekly blood 
counts in these studies as well and that the number of obtained blood samples from these 
studies did not differ too much from the other studies where weekly blood counts were 
mandated.   
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If the laboratory values were measured more than once per cycle, then the worst (minimum) 
value was considered.  When a specific laboratory value was not reported (missing value) but 
other laboratory data were reported at the same time, it was assumed that the specific toxicity 
was in the normal range and toxicity grade zero was imputed for that specific toxicity grade.   
Several potential confounders for the association of doxorubicin-induced toxicity and outcome 
were extracted from the database. The relative dose intensity (RDI) was calculated as the ratio 
of actual doxorubicin dose intensity (administered dose/actual duration of cycle in days) to the 
intended doxorubicin dose intensity (planned dose/standard cycle duration of 21 days) per 
cycle. For the calculation of administered dose, BSA was calculated using the weight value 
reported per patient by cycle and height value reported at baseline. When weight was missing, 
the last weight available was used for the calculation of RDI.  
Other characteristics assessed were demographic factors (age, gender and WHO performance 
status), and tumour characteristics (STS histological subtype, histopathological grading (low 
(grade I) versus high grade (grade II and III), time between initial diagnosis and start of 
chemotherapy, primary site, metastatic sites, and the presence of local recurrence and 
metastatic disease). 
 
Statistical analyses.  
Hematologic toxicity values and grades were summarised by cycle. The time between 
treatment start and occurrence of first toxicity grade was depicted using a Cumulative 
Incidence graph to investigate at which time higher grades of toxicity occurred. 
To compare the PFS and OS between patients with low (grade 0-2) versus those with high 
haematological toxicities (grade 3-4), Kaplan-Meier methods and the log-rank test were used. 
To avoid potential bias from patients who received only one, two or three cycles of treatment, 
landmark analyses were performed to compare the results at the end of cycle 1, cycle 2 and 
cycle 3. Patients who progressed, died or discontinued before the different landmark analyses 
were excluded from these analyses.  
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To explore whether RR differed between patients with or without high hematologic toxicities 
(0-2 vs 3-4), the Chi-square test was used for the subgroups of patients still on treatment at the 
end of cycle 1, cycle 2 and cycle 3. Patients who stopped treatment before each time point 
were excluded from these analyses. 
Associations between baseline characteristics (gender, body mass index, performance score, 
and age) and hematological grade 3/4 toxicity were established using logistic multivariate 
regression modeling. 
 
Results 
Patients’ characteristics. 
A total number of 557 sarcoma patients from 7 EORTC trials (conducted between 1990 and 
2012) were considered for this analysis. The analysis was based on patients who received at 
least 1 cycle of treatment, for a total number of cycles of 2341. 
The patients’ characteristics per protocol are depicted in table 1. The majority of patients (32%) 
were between 50 and 60 years old at registration, 51% were female.  Almost all patients had a 
PS of 0 or 1 and 72% had a grade II or III tumor. Leiomyosarcoma (28%) and liposarcoma (15%) 
were the most frequent STS subtypes entered in these studies. 
 
Treatment exposure. 
263 out of 557 (47.2%) patients received at least 6 cycles of treatment: 220 (39.5%) patients 
stopped treatment after 6 cycles and 43 (7.8%) received more than 6 cycles. The latter group 
concerned patients from the two oldest trials (62901 and 62941) in which a maximum of 8 and 
7 cycles, respectively, were allowed per protocol whereas in the more recent trials the 
maximum number of cycles was set at 6.  
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The median time on treatment, defined as the time in weeks between the start date of 
treatment and the end date of the last cycle reported (i.e. the date of administration of the last 
cycle of doxorubicin + 21 days), was 15 weeks (figure 1) corresponding with a median time on 
treatment of around 5 cycles. After 9 weeks of treatment (3 cycles), 63.7 % of the patients were 
still on treatment. 
Patients interrupted treatment mainly due to progressive disease (45%), only 19 patients (3%) 
stopped because of toxicities. Forty percent of patients completed the maximum number of 
cycles per protocol. The relative dose intensity was constant over cycles and was concentrated 
around 100% (figure 2). 
 
Hematologic toxicity. 
The distribution of the hematologic laboratory values over the first 6 cycles of chemotherapy is 
depicted in figure 3. The worst toxicity grade per cycle is displayed in figure 4. At baseline 90% 
of the patients had grade 0 or 1 toxicity. The percentage of patients having grade 2 toxicity 
increased over time from 17% at cycle 1 to 24% at cycle 3. After cycle 1 the percentage of 
patients experiencing grade 3 toxicity was quite constant over cycle, while the percentage of 
patients with grade 4 tended to decrease after cycle 1, from 21.0% at cycle 2 to 12% at cycle 3. 
This tendency was not related to the interruption of the treatment since the majority of 
patients with grade 3/4 toxicity during cycle 1 did generally not interrupt the treatment after 
cycle 1. Out of 106 patients with grade 3 and 118 patients with grade 4 at cycle 1, respectively, 
93 and 90% continued treatment after cycle 1 and 53 and 42%, respectively, were still on 
treatment at cycle 6, which is comparable with patients with grade 0-2 toxicity during cycle 1. 
 
Response to treatment and association with toxicity. 
91 (16.3%) patients had a CR or PR as best response, 453 (81.3%) patients had progression or 
stable disease. In patients with grade 0-2 toxicity as worst toxicity the RR was 11.8% (28/238 
patients), in patients with grade 3/4 toxicity the RR was 19.7% (63/319 patients). Since this 
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comparison could be biased by the fact that worst toxicity may have occurred after the best 
response on treatment, the relationship of response with the worst toxicity was separately 
done at cycle 1, 2 or 3 considering only patients still on treatment at that cycle. For patients 
with grade 0-2 toxicity versus those with grade 3/4 toxicity the respective RRs were 14.9% 
versus 19.0% at cycle 1 (p=0.44), 15.1% versus 20.2% at cycle 2 (p=0.264), and 21.0 versus 
25.2% at cycle 3 (p=0.435). 
 
Progression free survival and association with toxicity. 
539 (96.8%) patients progressed or died during follow-up; 18 (3.2%) patients were still alive 
without progression at the last available follow up. To investigate the influence of severity of 
toxicity on PFS, a landmark analysis was performed. Kaplan-Maier plots to compare the results 
at the end of cycle 1, 2 and 3 were made in which patients who died, progressed or 
discontinued treatment before each of those cut offs were not considered in the analysis. 
The median PFS (95% Confidence Interval (CI)) of patients with low hematologic toxicity (grade 
0-2) versus those with severe hematological toxicity (grade 3-4) during cycle 1 was 17.7 (12.7-
21.1) weeks versus 21.0 (15.0-24.3) weeks (HR 0.85 (0.71-1.01); p=0.066), during cycle 1-2, 21.2 
(19.1-24.6) weeks versus 15.8 (11.4-20.8) weeks (HR 0.91 (0.75-1.10); p=0.316), and during 
cycle 1 to 3, 27.9 (24.1-32.7) weeks versus 30.9 (27.4-32.9) weeks (HR 0.93 (0.75-1.16); 
p=0.518). 
Also for each specific hematologic toxicity (anemia, thrombocytopenia, leukocytopenia, and 
neutropenia) landmark analyses were conducted at the end of cycle 1, 2 and 3. Given the low 
number of patients experiencing thrombocytopenia grade 3/4 the analysis for 
thrombocytopenia was not possible. For none of the assessments done, was there a statistically 
significant difference in PFS between patients with low grades of toxicity versus those with high 
grades of toxicity. To illustrate, the PFS curves for the subgroups of patients with low versus 
high toxicity occurring during cycle 1-3 are depicted in figure 5. 
 
Overall survival and association with toxicity. 
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With respect to OS, 437 (78.5%) patients died during follow-up, while 120 (21.5%) patients 
were still alive at the last available follow up. For the association of hematologic toxicity and OS 
landmark analyses were also conducted using the same cut-offs as were used in the PFS 
analyses.    
The median OS (95% CI) of patients with low hematologic toxicity (grade 0-2) versus those with 
severe toxicity (grade 3-4) during cycle 1 was 52.1 (45.1 - 61.6) weeks versus 54.1 (46.3 - 63.6) 
weeks (HR 0.97 (0.80 - 1.17) p=0.739), during cycle 1-2 59.6 (49.7 - 67.0) weeks versus 55.2 
(49.1 - 65.9) weeks (HR 0.99 (0.81, 1.21); p=0.924), and during cycle 1-3, 67.0 (57.3 - 78.7) 
weeks versus 64.0 (54.1 - 72.1) weeks (HR 1.04 (0.82, 1.32)); p=0.729). 
Also for OS, analyses were done for each of the hematologic toxicities separately with the 
exception of thrombocytopenia given the low number of patients with greater than grade 3 
thromobocytopenia. As for PFS, there were no statistically significant associations between the 
occurrence of any of the hematologic toxicities assessed and OS. Results are shown for the 
subset of patients with time on treatment and OS ≥ 63 days (N=383). 
 
Baseline characteristics and grade 3/4 hematological toxicity. 
The association between the baseline characteristics (age, gender, BMI, and performance 
score) and grade 3/4 hematological toxicity is displayed in table 2. Female gender, higher age, 
and a low BMI appeared to be associated with grade 3/4 hematological toxicity, in particular 
grade 3/4 neutropenia. 
 
 
Discussion.  
In this large series of advanced STS patients treated with doxorubicin monotherapy, we have 
identified several predictors for doxorubicin-induced hematological toxicity, but could not 
demonstrate an association of treatment-induced toxicity with outcome.  
After administration, doxorubicin is partially converted into several metabolites with 
doxorubicinol being the major metabolite (6, 8, 9). Like almost all anti-tumour agents, the 
pharmacokinetics of doxorubicin and its metabolites vary widely between patients with inter-
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individual coefficients of variation for area under the curve, volume of distribution, and 
clearance being in the range of 60-90% (6, 8). Several mechanisms may underlie this inter-
individual variation including differences in hepatic function (6), gender, BMI (5) and genetic 
variants in genes encoding products involved in the metabolism of doxorubicin (10).  
Several previous studies have underlined the importance of pharmacokinetics for doxorubicin-
induced adverse events. For example, doxorubicin-induced cardiotoxicity has been suggested to 
be maximum-concentration dependent, and should in that respect be given as an infusion 
rather than as a bolus, while leucopenia is more related to the AUC (10). In a study in patients 
with small cell lung cancer, there appeared to be a strong correlation between the AUC of 
doxorubicin and leucocytes, while no relationships were found for hematologic toxicity with 
levels of doxorubicin’s main metabolite, doxorubinicol (6). In the study population described 
here in which 93% of patients had a good WHO performance score (0-1), doxorubicin was 
generally very well tolerated. The RDI in those patients who did not have to terminate 
treatment because of progressive disease, remained constant at 100% over treatment and only 
3% of the patients had to terminate treatment for reasons of toxicity. To assess the relationship 
between doxorubicin-induced toxicity and outcome we focused on hematologic parameters 
since these are not largely impacted by factors other than the administrated chemotherapy and 
can be relatively easily captured. Of the toxicities assessed, leucopenia and neutropenia grade 
3/4 occurred most often, grade 3/4 thrombocytopenia was very rare. Importantly, hematologic 
toxicity appeared not to be cumulative after cycle 1 with occurrence of grade 3 toxicity 
remaining constant over the diverse cycles while grade 4 toxicity even tended to decrease after 
cycle 1. Taken together, these data again emphasize the good tolerability of doxorubicin in this 
group of advanced patients, which is of great importance in the palliative setting.  
Compared to toxicity, data on a dose-response relationship for anti-tumor effects of 
doxorubicin are very scarce. In pre-clinical models, in particular cell line models, there is in 
general a clear dose-response relationship but to what extent these data can be extrapolated to 
humans is unknown. One paper suggests that doxorubicin should be given at doses higher than 
70 mg/m2 (7) but the underlying evidence for this is rather weak.  
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Nevertheless, in view of the assumed dose-response relations for both anti-tumor effects and 
hematologic toxicity, one could anticipate an association between toxicity and anti-tumor 
effects. This expectation is also commonly shared by patients. In our experience, many patients 
can become concerned when they don’t experience toxicity during treatment and ask “whether 
or not the chemotherapy actually works, and whether the dose is high enough”.  In this study 
however, we could not find an association between any of the explored hematologic toxicities 
and outcome in terms of RR, PFS, and OS. This information is important as it may be useful to 
reassure advanced STS patients that failure to experience haematological toxicity during 
treatment does not equate to under-treatment and patients have not to be worried if they do 
not experience some greater toxicity as it does not reflect their response to therapy.  
Apart from the fact that there is indeed no association at all between hematologic toxicity and 
outcome, there are several reasons to be considered why we could not identify such a 
relationship. In patients with advanced STS, numerous patient- as well as tumor-related factors 
have been found to determine outcome to doxorubicin, including WHO performance, gender, 
and histologic subtype (12, 13). As a result, a weak to modest association between hematologic 
toxicity and outcome could therefore be obscured. In this study, subanalyses to establish 
whether there was a relationship between doxorubicin-toxicity and outcome in specific 
histopathological subgroups were not additionally performed since it is unlikely that tumor 
characteristics such as histological subtype or tumor grading impact the toxicity to doxorubicin. 
Additionally, we would end up with relatively small groups of patients hindering to establish 
robust conclusions. 
Another reason underlying the lack of association between toxicity and outcome might be that 
doxorubicin levels reached in tumors, which are needed to exert anti-tumor effects, could differ 
from the levels reached in bone marrow causing myelosuppression. Many tumors are 
characterized by leaky tumor vasculature, which results in a high intra-tumoral interstitial 
pressure. This can hamper the penetration of drugs from the peripheral circulation into tumors, 
although this can differ per cytotoxic drug. For example, in studies where simultaneously blood 
levels as well as intra-tumoural levels were measured, 5FU levels in tumors appeared to be 
substantially lower in tumors compared to blood whereas for carboplatin no difference could 
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be revealed (14, 15). To the best of our knowledge such data have not yet been generated yet 
for doxorubicin. Further investigations to determine the relationship between both blood drug 
levels and toxicity, and between blood drug levels, intra-tumoural drug concentrations, and 
anti-tumor effects are therefore necessary.   
In addition to examining the relationship between toxicity and outcome, we explored whether 
or not the baseline characteristics age, gender, BMI, and performance score) were associated 
with the occurrence of grade 3/4 hematological toxicity. It was revealed that female gender, 
higher age, and a low BMI were associated with an increased risk of grade 3/4 hematological 
toxicity, in particular grade 3/4 neutropenia. Previous research on the impact of these baseline 
characteristics on toxicity from doxorubicin-based chemotherapy is rather scarce. In a recent 
meta-analysis on the effect of obesity on outcome of adjuvant doxorubicin-based 
chemotherapy in early breast cancer, it was found that in general obese patients experienced 
less toxicity (16). That the association between body composition and doxorubicin’s 
pharmacokinetics is rather complex, is underlined by a study showing that the systemic 
clearance of doxorubicin is reduced in obese women, but not in obese men (5). The effect sizes 
seen in our study, particularly for the association between age and neutropenia grade 3/4, are 
substantial taking into account the often-delicate balance between anticipated benefits versus 
untoward events when treating elderly advanced STS patients and justify further research in 
this area.    
There are several limitations of this analysis. The retrospective nature of this study renders it 
prone to all the different sources of bias inherent to retrospective analyses. Additionally, we 
focused on hematological toxicities only and not on other toxicities. Another limitation is the 
fact that patients included into clinical trials are often not reflective for the populations seen in 
daily clinical practice. As a consequence, the findings in our study may be generally applicable. 
Strong points of this study are the large number of patients and the homogeneity in terms of 
treatment given and patient’s and tumor characteristics since the eligibility criteria of the 
clinical studies used in this analysis changed little over the years.     
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In conclusion, in this large series of advanced STS patients receiving doxorubicin monotherapy, 
treatment appeared to be very well tolerated with almost no patients having to stop treatment 
because of toxicity. This again confirms the tolerability of doxorubicin monotherapy in patients 
with advanced STS, which is crucial given the palliative setting of this treatment. Furthermore, a 
relation between severity of hematologic toxicity and outcome could not be demonstrated, 
which is reassuring for patients who are concerned they being undertreated when toxicity fails 
to occur. 
 
 
 
Statement: none of the authors have an interest that may have a bearing on this manuscript.  
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Table 1: Patient characteristics 
Patient's characteristics by protocol 
 
Protocol  
62901 
(N=101) 
62941 
(N=38) 
62962 
(N=41) 
62971 
(N=99) 
62012 
(N=203) 
62061 
(N=37) 
62091 
(N=38) 
Total 
(N=557) 
 N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
Gender                                                                                                                                                                                                                                                                                                                                                                                                                                
 Male                      49 (48.5)                                                                                           22 (57.9)                         18 (43.9)                       51 (51.5)                       95 (46.8)                           21 (56.8)                                                                 16 (42.1)                              272 (48.8)                                             
 Female                    52 (51.5)                                                                                           16 (42.1)                         23 (56.1)                       48 (48.5)                        108 (53.2)                                 16 (43.2)                                                          22 (57.9)                                               285 (51.2)                                               
Age                                                                                                                                                                                                                                                                                                                                                                                                                                    
 < 40 yrs                  14 (13.9)                                                                                           10 (26.3)                         5 (12.2)                                             21 (21.2)                                            48 (23.6)                         0 (0.0)                         2 (5.3)                                                            100 (18.0)                          
 40-50 yrs                 28 (27.7)                                                                                          7 (18.4)                       14 (34.1)                                               26 (26.3)                       74 (36.5)                          0 (0.0)                         4 (10.5)                                                            153 (27.5)                          
 50-60 yrs                 32 (31.7)                                                                                           11 (28.9)                         11 (26.8)                       32 (32.3)                       74 (36.5)                           9 (24.3)                           11 (28.9)                          180 (32.3)                        
 >=60 yrs                  27 (26.7)                                                                                           10 (26.3)                         11 (26.8)                       20 (20.2)                          7 (3.4)                       28 (75.7)                                                                               21 (55.3)                                         124 (22.3)                                          
Performance status                                                                                                                                                                                                                                                                                                                                                                                                                           
 PS 0                      32 (31.7)                                                                                           11 (28.9)                         10 (24.4)                       46 (46.5)                        115 (56.7)                        20 (54.1)                                                                   25 (65.8)                                                    259 (46.5)                                          
 PS 1                      57 (56.4)                                                                                           24 (63.2)                         26 (63.4)                       53 (53.5)                       88 (43.3)                           17 (45.9)                                                                 13 (34.2)                        278 (49.9)                                                
 PS 2+                     12 (11.9)                                                                                          3 (7.9)                       5 (12.2)                      0 (0.0)                         0 (0.0)                           0 (0.0)                                                                 0 (0.0)                        20 (3.6)                                                   
 
Histopathological aggressivity  
                                                                                                                                                                                                                                                                                                                                                                                                             
 Low                   16 (15.8)                                                                                          9 (23.7)                       4 (9.8)                      8 (8.1)                      13 (6.4)                          5 (13.5)                                                                                         0 (0.0)                         55 (9.9)                                               
 High                  60 (59.4)                                                                                           14 (36.8)                         14 (34.1)                       91 (91.9)                        190 (93.6)                                 32 (86.5)                                                          4 (10.5)                         405 (72.7)                                                  
 Missing                 25 (24.8)                                                                                           15 (39.5)                         23 (56.1)                      0 (0.0)                                                                    0 (0.0)                         0 (0.0)                                            34 (89.5)                                             97 (17.4)                                                                   
Site of primary tumor                                                                                                                                                                                                                                                                                                                                                                                                                        
 Other                     27 (26.7)                                                                                           18 (47.4)                         29 (70.7)                       56 (56.6)                        113 (55.7)                        26 (70.3)                                                                   27 (71.1)                                                    296 (53.1)                                          
 Extremities                      11 (10.9)                                                                                           17 (44.7)                         12 (29.3)                       41 (41.4)                       89 (43.8)                           10 (27.0)                                                                 9 (23.7)                                                189 (33.9)                                                
 Missing                   63 (62.4)                                                                                          3 (7.9)                       0 (0.0)                      2 (2.0)                         1 (0.5)                           1 (2.7)                                                                 2 (5.3)                        72 (12.9)                                                       
Histology                                                                                                                                                                                                                                                                                                                                                                                                                                    
 Leiomyosarcoma                      43 (42.6)                                                                                           11 (28.9)                         9 (22.0)                                             21 (21.2)                                            42 (20.7)                         15 (40.5)                                             12 (31.6)                              153 (27.5)                                             
 Synovial sarcoma                     7 (6.9)                                                                                           4 (10.5)                                                   4 (9.8)                                        10 (10.1)                                                                   34 (16.7)                         1 (2.7)                         4 (10.5)                                                                64 (11.5)                                               
 Liposarcoma                      14 (13.9)                                                                                          6 (15.8)                       7 (17.1)                       15 (15.2)                                                                    23 (11.3)                         8 (21.6)                          12 (31.6)                          85 (15.3)                                                               
 Other                     34 (34.0)                                                                                           17 (24.5)                         21 (28.3)                       52 (54.7)                        84 (41.7)                       13 (38.8)                                                                     10 (30.9)                                              231 (41.5)                                               
 Missing                    3 (3.0)                                                                                           0 (0.0)                                                                  0 (0.0)                                1 (1.0)                           20 (9.9)                        0 (0.0)                                                                       0 (0.0)                                           24 (4.3)                                               
Prior Surgery                                                                                                                                                                                                                                                                                                                                                                                                                                
 No surgery                          0 (0.0)                                                                                           4 (10.5)                                                   4 (9.8)                                        22 (22.2)                                                                  203 (100.0)                            37 (100.0)                                          38 (100.0)                            105 (18.9)                                         
 Non optimal surgery                 0 (0.0)                                                                                           5 (13.2)                                                   11 (26.8)                                             13 (13.1)                      0 (0.0)                       0 (0.0)                         0 (0.0)                                      29 (5.2)                                                
 Complete surgery                    0 (0.0)                                                                                           22 (57.9)                        20 (48.8)                      55 (55.6)                      0 (0.0)                         0 (0.0)                         0 (0.0)                           97 (17.4)                                                       
 Missing                  101 (100.0)                                                                                          7 (18.4)                                                                      6 (14.6)                           9 (9.1)                      0 (0.0)                            0 (0.0)                                                                  0 (0.0)                        326 (58.5)                          
Prior radiotherapy                                                                                                                                                                                                                                                                                                                                                                                                                           
 No                        77 (76.2)                                                                                           19 (50.0)                         29 (70.7)                       75 (75.8)                        130 (64.0)                                 37 (100.0)                                                         38 (100.0)                                               405 (72.7)                                               
 Yes                       24 (23.8)                                                                                           19 (50.0)                         12 (29.3)                       23 (23.2)                       73 (36.0)                           0 (0.0)                         0 (0.0)                                                 151 (27.1)                          
 Missing                    0 (0.0)                                                                                           0 (0.0)                                                                  0 (0.0)                                1 (1.0)                           0 (0.0)                           0 (0.0)                                                                 0 (0.0)                        1 (0.2)                                       
Primary site involved                                                                                                                                                                                                                                                                                                                                                                                                                        
 No                         0 (0.0)                                                                                           25 (65.8)                        19 (46.3)                      46 (46.5)                      110 (54.2)                                 15 (40.5)                                                          21 (55.3)                                               236 (42.4)                                               
 Yes                        0 (0.0)                                                                                           13 (34.2)                        22 (53.7)                      53 (53.5)                        93 (45.8)                           17 (45.9)                                                                 17 (44.7)                              215 (38.6)                                             
 Missing                  101 (100.0)                                                                                          0 (0.0)                                                                                0 (0.0)                      0 (0.0)                      0 (0.0)                           5 (13.5)                                                                 0 (0.0)                        106 (19.0)                          
Metastatic Site involved                                                                                                                                                                                                                                                                                                                                                                                                                     
 No                         0 (0.0)                                                                                           3 (7.9)                                                                  4 (9.8)                                13 (13.1)                                                                  0 (0.0)                       7 (18.9)                         5 (13.2)                                          32 (5.7)                                                
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Patient's characteristics by protocol 
 
Protocol  
62901 
(N=101) 
62941 
(N=38) 
62962 
(N=41) 
62971 
(N=99) 
62012 
(N=203) 
62061 
(N=37) 
62091 
(N=38) 
Total 
(N=557) 
 N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
 Yes                        0 (0.0)                                                                                           35 (92.1)                        37 (90.2)                      86 (86.9)                      189 (93.1)                        30 (81.1)                                                                   33 (86.8)                                                    410 (73.6)                                          
 Missing                  101 (100.0)                                                                                          0 (0.0)                                                                                0 (0.0)                      0 (0.0)                      14 (6.9)                        0 (0.0)                                                                      0 (0.0)                                             115 (20.6)                          
 
 
Table 2: Association of baseline characteristics and hematological toxicity experienced. (Odds ratio 
estimates and corresponding 95% CI from a logistic multivariate regression) 
Parameter Any AE grade 3-4 HGB: grade 3-4* WBC: grade 3-4 NEU: grade 3-4 
Value at baseline 1.24 (0.93; 1.66) 11.4 (5.34; 24.2) 1.37 (0.59; 3.15) 1.17 (0.58; 2.34) 
  P = 0.143 P < 0.001 P = 0.464 P = 0.661 
Age <40 yrs 0.28 (0.15; 0.51) 0.13 (0.02; 0.71) 0.43 (0.24; 0.76) 0.30 (0.16; 0.54) 
 40-50 yrs 0.23 (0.13; 0.40) 0.59 (0.21; 1.69) 0.33 (0.20; 0.56) 0.24 (0.14; 0.41) 
 50-60 yrs 0.32 (0.19; 0.54) 0.60 (0.22; 1.61) 0.31 (0.19; 0.50) 0.33 (0.20; 0.55) 
 >= 60 yrs 1.00 1.00 1.00      1.00 
  P < 0.001 P = 0.132 P < 0.001 P < 0.001 
BMI <18.5  5.49 (1.42; 21.2) 2.36 (0.25; 22.5) 2.93 (0.96; 8.98) 7.60 (1.99; 29.0) 
 18.5 – 25  1.86 (1.19; 2.88) 0.94 (0.38; 2.30) 1.49 (0.95; 2.34) 2.31 (1.49; 3.58) 
 25 – 30 1.64 (1.03; 2.62) 0.72 (0.26; 2.01) 1.24 (0.77; 2.00) 2.00 (1.26; 3.18) 
 >= 30 1.00 1.00 1.00 1.00 
  P = 0.007 P = 0.763 P = 0.146 P < 0.001 
PS 0 0.43 (0.14; 1.34) 1.50 (0.24; 9.25) 0.67 (0.25; 1.83) 0.66 (0.24; 1.83) 
 1 0.40 (0.13; 1.22) 1.19 (0.21; 6.80) 0.77 (0.28; 2.08) 0.59 (0.21; 1.64) 
 2+ 1.00 1.00 1.00 1.00 
  P = 0.268 P = 0.826 P = 0.624 P = 0.554 
Gender Female 1.91 (1.32; 2.76) 0.75 (0.34; 1.64) 1.51 (1.05; 2.19) 1.69 (1.18; 2.43) 
 Male 1.00 1.00 1.00 1.00 
  P < 0.001 P = 0.468 P = 0.028 P = 0.004 
* Very few “events” so results are very unstable 
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Figure 1. Time on treatment 
 
 
 
Figure 2. Relative dose intensity (RDI).  
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RDI (i.e. the actual dose intensity compared to the theoretical one, in %). RDI1 is relative dose intensity during 
cycle 1, RDI2 during cycle 2, RDI3 during cycle 3. 
 
  
22 
 
 
Figure 3 Worst hematological toxicity per cycle. 
 
 
 
 
X-axis: “0” refers to values observed at baseline.   
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Figure 4: worst overall toxicity grade per cycle. 
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Figure 5.  Subgroup of patients with time on treatment and PFS ≥ 63 days (N=348) for each haematological toxicity grade 
during C1-3 
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Figure 6 
Subgroup of patients with time on treatment and OS ≥ 63 days (N=383) for each hematological toxicity grade during C1-3  
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Supplementary Table. 
 
Table 1: Studies considered for the analysis:  
Study 
N pts per 
study 
N pts 
randomized 
to DOX 75 
N pts considered 
in this analysis 
References 
(First author, year, title, Journal) 
EORTC 
62901 
R. Ph II/III 
334 112 101 
O.S. NIELSEN et al. (1998), High-dose epirubicin is not an alternative to 
standard-dose doxorubicin in the treatment of advanced soft tissue 
sarcomas. A study of the EORTC Soft Tissue and Bone Sarcoma Group. 
Br.J. Cancer 78 (12): 1634-1639 
EORTC 
62941 
R. Ph II 
86 42 38 
J. VERWEIJ et al. (2000), Randomized phase II study of docetaxel versus 
doxorubicin in first- and second-line chemotherapy for locally advanced or 
metastatic soft tissue sarcomas in adults: A study of the European 
organization for research and treatment of cancer soft tissue and bone 
sarcoma group. J Clin Oncol 18: 2081-2086 
EORTC 
62962 
R. Ph II 
95 45 41 
I. JUDSON et al. (2001), Randomised phase II trial of pegylated liposomal 
doxorubicin (Doxil®/Caelyx®) versus doxorubicin in the treatment of 
advanced or metastatic soft tissue sarcoma: A study by the EORTC soft 
tissue and bone sarcoma group. Eur J Cancer 37: 870-877 
EORTC 
62971 
R. Ph III 
326 110 99 
P. LORIGAN et al. (2007), Phase III Trial of two investigational schedules of 
Ifosfamide compared with standard-dose Doxorubicin in advanced or 
metastatic soft tissue sarcoma: A European Organisation for Research and 
Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin 
Oncol 25 (21): 3144-3150 
EORTC 
62012 
R. Ph III 
445 228 203 
I JUDSON et al. (2014), Doxorubicin alone versus intensified doxorubicin 
plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue 
sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. S1470-
2045(14)70063-4 
EORTC 
62061 
R. Ph II 
118 39 37 
H. GELDERBLOM H et al. (2014), Brostallicin versus doxorubicin as first-line 
chemotherapy in patients with advanced or metastatic soft tissue sarcoma: 
an European Organisation for Research and Treatment of Cancer Soft 
Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic 
study. Eur J Cancer. 50(2):388-96 
EORTC 
62091 
R. Ph II/III 
133 43 38 
B. BUI-NGUYEN et al (2015). A phase IIB multicenter study comparing the 
efficacy of trabectedin to doxorubicin in patients with advanced or metastatic 
untreated soft tissue sarcoma: the TRUSTS trial. Eur J Cancer. 51 (10): 
1312-20. 
R=randomised; DOX=doxorubicin. 
 
 
 
 
 
 
